<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Qual Life Outcomes</journal-id><journal-title>Health and Quality of Life Outcomes</journal-title><issn pub-type="epub">1477-7525</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15771777</article-id><article-id pub-id-type="pmc">PMC555754</article-id><article-id pub-id-type="publisher-id">1477-7525-3-14</article-id><article-id pub-id-type="doi">10.1186/1477-7525-3-14</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Subjective impact of osteoarthritis flare-ups on patients' quality of life</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Majani</surname><given-names>Giuseppina</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gmajani@fsm.it</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Giardini</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>agiardini@fsm.it</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Scotti</surname><given-names>Aurelio</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>a.scotti@italfarmaco.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Psychology Unit, Fondazione S. Maugeri, Clinica del Lavoro e della Riabilitazione, IRCCS, Istituto Scientifico di Montescano (PV), Italy</aff><aff id="I2"><label>2</label>Scientific Department, Italfarmaco SpA, Milan, Italy</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2005</year></pub-date><volume>3</volume><fpage>14</fpage><lpage>14</lpage><ext-link ext-link-type="uri" xlink:href="http://www.hqlo.com/content/3/1/14"/><history><date date-type="received"><day>7</day><month>1</month><year>2005</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Majani et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Majani et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Majani
               Giuseppina
               
               gmajani@fsm.it
            </dc:author><dc:title>
            Subjective impact of osteoarthritis flare-ups on patients' quality of life
         </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>Health and Quality of Life Outcomes 3(1): 14-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7525(2005)3:1&#x0003c;14&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7525</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Clinical trials on osteoarthritis (OA) flare-ups treatment usually focus only on objective measures of health status, albeit recent literature suggestions on the importance of patients' subjectivity. Aim of the study was to evaluate the effects of OA and of its different types of medical treatment(s) on Health Related Quality of Life (HRQoL) in terms of both subjective satisfaction and functional status.</p></sec><sec sec-type="methods"><title>Methods</title><p>An observational study on prospective data collected from the Evaluation of Quality of life in OA (EQuO) clinical trial (April 1999-November 2000) was conducted; outpatients from 70 participating centers (Orthopedy or Rheumatology Departments in Italy) with a diagnosis of OA of the hip or knee were consecutively enrolled. Patients were observed at OA flare-ups (baseline) and at follow up 4 weeks after treatment. Patients' objective and subjective HRQoL were assessed by means of the SF-36 and the Satisfaction Profile (SAT-P, which focuses on subjective satisfaction); Present Pain at baseline and Pain Relief at follow up were also evaluated.</p></sec><sec><title>Results</title><p>Among the 1323 patients, 1138 (86%) were prescribed one drug/treatment of osteoarthritis, 169 (13%) 2 drugs/treatments, and 16 (1%) 3 drugs/treatments; most of treatments involved the prescription of NSAIDs; non-coxib, COX2 selective NSAIDs were prescribed in about 50% of patients. Follow-up visits were performed after 29.0 days on average (&#x000b1; 7.69 SD). For all SF-36 domains, all SAT-P items and factors, the differences between baseline and follow up scores resulted statistically significant (p &#x0003c; 0.001), enlighting an improvement both in health status and in subjective HRQoL.</p></sec><sec><title>Conclusion</title><p>Besides the classic health status measures, the assessment of patients' subjective satisfaction provides important clues on treatments efficacy of OA within the patient-centered medicine model. In clinical practice this could lead to a better doctor-patient communication and to higher levels of treatment adherence.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The impact of osteoarthritis (OA) on patient's functional levels is well known [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Pain and physical limitations constitute difficulties patients have to deal with [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>] and require long term pharmacological treatment and physical therapies.</p><p>Usually OA affects elderly people, and is one of the main causes of physical disability. In OA patients, Health Related Quality of Life (HRQoL) and activities of daily living are negatively affected. Significant work disability, reduced ability to deal with household duties and sleep disorders are reported in patients with symptoms of OA flare-ups, together with dysfunctions in the areas of ambulation, body-care and movement (in terms of perceived health status), and emotional behaviour (in terms of perceived psychological functioning) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B8">8</xref>].</p><p>As a chronic condition, the impact of OA has been studied mainly focusing on its consequences on health status. Similarly, treatment efficacy is assessed within the context of health status and/or symptomatology in many clinical trials [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. However, health status and symptomatology can be considered only two components of HRQoL [<xref ref-type="bibr" rid="B13">13</xref>] and little is known about the impact of OA and its treatments on patient's subjective perspective, in spite of increasing attention on this topic [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B19">19</xref>].</p><p>In literature, HRQoL refers to patients' appraisals of their current levels of functioning and satisfaction, compared to what they perceive to be ideal [<xref ref-type="bibr" rid="B20">20</xref>]. HRQoL assessment allows a subject to express his or her ability to perform daily activities across many domains which include physical, social and cognitive functioning, role activities and emotional wellbeing. Besides, "...how a subject feels about the performace of each of those activities may be assessed separately by measuring satisfaction for each domain." [<xref ref-type="bibr" rid="B21">21</xref>]. The subjective implications of HRQoL, within the context of patient centred medicine, have been already stressed by suggestions from recent reliable scientific literature [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B24">24</xref>].</p><p>The aim of the present study is to evaluate the effects of OA and of its different types of medical treatment(s) on HRQoL in terms of both subjective satisfaction and functional status.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient population and procedure</title><p>Data from collaborating, educated outpatients aged 50&#x02013;80 years with a diagnosis of OA of the hip or knee according to the criteria of the American College of Rheumatology [<xref ref-type="bibr" rid="B25">25</xref>] were collected in this observational, prospective study.</p><p>Outpatients (n = 1340) were consecutively enrolled in 70 Italian participating centers (Orthopedy or Rheumatology Departments, listed in Appendix A [see additional file]) from April 1999 to November 2000. 147 patients withdrawn OA treatment before follow-up visit.</p><p>All patients signed an informed consent in which the purposes of the study (HRQoL assessment and treatment efficacy, as primary and secondary outcomes respectively) were clearly stated. Approval for this research was obtained by the ethics committee, patients did not receive any remuneration for their participation.</p><p>Patients with concomitant osteoarticular disorders, impairment of motor function not due to OA of the hip or knee, concomitant systemic disease(s) affecting HRQoL or requiring NSAIDs/steroids use on a regular basis were not included into the study, in order to avoid biases in the results due to treatments other than OA treatments.</p><p>Patients were observed at OA flare-ups, when attending for a visit (baseline) and at follow up 4 weeks after treatment. According to the observational design of this trial, no "study treatments" were assigned to patients, but any drug(s)/medical treatment(s) considered by the physician as adequate to the patient's clinical condition was freely prescribed; therefore patients were not previously randomized to treatment.</p><p>During both visits, patients were administered the following: the Visual Analogue Scale (VAS) [<xref ref-type="bibr" rid="B26">26</xref>] on Present Pain (baseline) or on Pain Relief (follow up); the Medical Outcomes Study Short-Form 36 Health Status Survey (SF-36) [<xref ref-type="bibr" rid="B27">27</xref>] in its validated Italian version [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>] and the Satisfaction Profile (SAT-P) [<xref ref-type="bibr" rid="B30">30</xref>].</p><p>Moreover, at follow up, the global assessments of efficacy and tolerability of the medical treatment(s) prescribed for OA flare ups (expressed by the patient and by the physician according to a 4 point semi-quantitative rating scale: excellent &#x02013; good &#x02013; moderate &#x02013; poor) were collected. Side effects to this/these treatment(s), if any, were registered as well.</p><p>The assessment procedure was standardized for all the participating centres. During the visit patients were invited to compile alone all the questionnaires and rating scales, only if required patients were assisted by a trained health professional.</p><p>Self-reporting bias in HRQoL improvements was kept under control by the assessment procedure and by the adoption of valid and reliable questionnaires.</p></sec><sec><title>Measures</title><sec><title>Visual Analogue Scale</title><p>The VAS is perhaps the most widely used instrument for the measurement of pain intensity. The classic version of the VAS was administered: 10 centimeter line, horizontal. "It is a simple, robust, sensitive, and reproducible instrument that enables a patient to express the severity of his pain in such a way that it can be given a numerical value." [<xref ref-type="bibr" rid="B26">26</xref>] Its psychometric properties and its utility in clinical trials have been confirmed [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. VAS on Present Pain ranged from "no pain" to "the worst pain possible"; VAS on Pain Relief ranged from "no pain relief" to "the maximum pain relief". Scores ranged from 0 to 100.</p></sec><sec><title>SF-36</title><p>The SF-36 is a well known self-administered and generic health status measure which encompasses 8 domains related to daily life activities: physical functioning, role limitations due to physical problems, role limitations due to emotional problems, vitality, bodily pain, social functioning, mental health and general health perception [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>]. Each domain scores from 0 (lowest level of functioning) to 100 (highest level of functioning). The instrument has been extensively validated within the Medical Outcome Study [<xref ref-type="bibr" rid="B33">33</xref>] and in other settings [<xref ref-type="bibr" rid="B34">34</xref>].</p></sec><sec><title>Satisfaction Profile</title><p>The SAT-P is a self-administered, generic questionnaire which provides a satisfaction profile in daily life and can be considered as an indicator of subjective QoL. Satisfaction can be defined as the cognitive product of the comparison between ideal life and reality, and can therefore be quantitatively measured. The subject is asked to evaluate his/her satisfaction about 32 life aspects with reference to the last month (on 32 10 cm horizontal VAS) independently of his/her objective health status (for example: "How satisfied have you been in the last month with your Resistance to physical fatigue?"; "How satisfied...with your Mood?"; "How satisfied...with your Emotional stability?"). It provides 32 individual scores and 5 factor scores, all ranging from 0 (lowest level of satisfaction) to 100 (highest level of satisfaction). Together with its ability to detect patient's subjective satisfaction, the SAT-P addresses some aspects of daily life which are not included in SF-36 items (i.e. sleep, sexual life, quality of couple relationship, eating, self-confidence, resistance to stress, etc.). Its psychometric properties and clinical utility have been confirmed [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>].</p></sec></sec><sec><title>Statistical analyses</title><p>Sociodemographic data and clinical values were analysed by means of descriptive statistics. Since the incidence of withdrawals resulted low, analyses were performed on complete cases and no solutions for handling missing data was adopted.</p><p>Baseline and follow-up of SF-36 and SAT-P item and factor scores were compared by means of Analusis of Covariance (ANCOVA). Moreover, ANCOVAs were adopted in order to evaluate the impact of clinical variables on SF-36 and SAT-P factor delta scores (calculated subtracting the follow-up scores from baseline scores). The variables included into the models were: age, gender, body weight, OA localization (hip, knee, or both), VAS Present Pain, presence of concomitant disease(s), type of treatment (COX2 selective NSAIDs vs. other treatments). Results were summarized using mean &#x000b1; SE for continuous variables and frequency (absolute and percent) for categorical variables. All p values are two-tailed and p &#x0003c; .05 was considered statistically significant. All computations were carried-out by resorting to SAS 8.0 procedures.</p></sec></sec><sec><title>Results</title><p>Patients demographic and clinical characteristics (OA localization (hip/knee/both), VAS Present Pain, type of medical treatment(s) of OA flare-ups, concomitant diseases and treatments are shown in Table <xref ref-type="table" rid="T1">1</xref>. Patients' baseline VAS Present Pain resulted consistent with a clinical condition of moderate to severe rheumatic disease.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patients' characteristics</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Gender (F/M)</td><td align="left">795/528</td></tr><tr><td align="left">Age (years, mean &#x000b1; SD)</td><td align="left">64.4 &#x000b1; 10.3</td></tr><tr><td align="left">Marital status:</td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Single, n (%)</td><td align="left">72 (5.4)</td></tr><tr><td align="left">&#x02003;&#x02003;Married, n (%)</td><td align="left">922 (69.7)</td></tr><tr><td align="left">&#x02003;&#x02003;Widowed, n (%)</td><td align="left">220 (16.6)</td></tr><tr><td align="left">&#x02003;&#x02003;Separated/divorced, n (%)</td><td align="left">13 (1.0)</td></tr><tr><td align="left">&#x02003;&#x02003;Missing, n(%)</td><td align="left">96 (7.3)</td></tr><tr><td align="left">Educational level:</td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Primary school, n (%)</td><td align="left">548 (41.4)</td></tr><tr><td align="left">&#x02003;&#x02003;Junior high school, n (%)</td><td align="left">325 (24.6)</td></tr><tr><td align="left">&#x02003;&#x02003;Senior high school, n (%)</td><td align="left">280 (21.2)</td></tr><tr><td align="left">&#x02003;&#x02003;Degree/Master/PhD, n (%)</td><td align="left">103 (7.7)</td></tr><tr><td align="left">&#x02003;&#x02003;Missing, n(%)</td><td align="left">67 (5.1)</td></tr><tr><td align="left">Employment status:</td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Employed, n (%)</td><td align="left">434 (32.8)</td></tr><tr><td align="left">&#x02003;&#x02003;Retired, n (%)</td><td align="left">550 (41.6)</td></tr><tr><td align="left">&#x02003;&#x02003;Housewife, n (%)</td><td align="left">288 (21.8)</td></tr><tr><td align="left">&#x02003;&#x02003;Missing, n (%)</td><td align="left">51 (3.8)</td></tr><tr><td align="left">Body weight (kg, mean &#x000b1; SD)</td><td align="left">73.4 &#x000b1; 11.0</td></tr><tr><td align="left">OA localization:</td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Knee, n (%)</td><td align="left">658 (49.7)</td></tr><tr><td align="left">&#x02003;&#x02003;Hip, n (%)</td><td align="left">463 (35.1)</td></tr><tr><td align="left">&#x02003;&#x02003;Knee + hip, n (%)</td><td align="left">202 (15.2)</td></tr><tr><td align="left">VAS Present Pain (mm, mean &#x000b1; SD)</td><td align="left">67.7 &#x000b1; 17.0</td></tr><tr><td align="left">Concomitant diseases, n (%)</td><td align="left">632 (47.8)</td></tr><tr><td align="left">Concomitant treatments, n (%)</td><td align="left">444 (33.6)</td></tr></tbody></table></table-wrap><p>The most frequent concomitant diseases were: hypertension (19.1%), metabolic and nutritional disorders (9.2%), muscoloskeletal, connective tissue and bone disorders (8.2%) and gastrointestinal system disorders (4.3%). The most frequently prescribed concomitant treatments were: cardiologic drugs (9.7%) and antihypertensive (9.4%), antidiabetic drugs (8.4%), antithrombotic agents (4.5%), antiacids (6.7%), sedatives (4.8%). 1138 patients (86%) were prescribed one drug/treatment of OA, 169 patients (13%) 2 drugs/treatments, and 16 patients (1%) received 3 drugs/treatments. Most of treatments involved the prescription of NSAIDs; non-coxib, COX2 selective NSAIDs (nimesulide betadex and nimesulide, the only two COX2 selective NSAIDs available in Italy at the time of this study) were prescribed in about 50% of patients (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Treatments prescribed for osteoarthritis flare-ups</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">n</td><td align="left">% patients</td></tr></thead><tbody><tr><td align="left">COX2 NON-SELECTIVE NSAIDs</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Arylacetic acid derivatives (diclofenac, indomethacin, sulindac, etc.)</td><td align="left">221</td><td align="left">16.7</td></tr><tr><td align="left">&#x02003;&#x02003;Arylpropionic acid derivatives (ibuprofen, naproxen, ketoprofen, etc.)</td><td align="left">165</td><td align="left">12.5</td></tr><tr><td align="left">&#x02003;&#x02003;Oxycams (piroxicam, tenoxicam, etc.)</td><td align="left">181</td><td align="left">13.7</td></tr><tr><td align="left">&#x02003;&#x02003;Others (nabumetone, glucosamine, diacerein, etc.)</td><td align="left">107</td><td align="left">8.1</td></tr><tr><td align="left">COX2 SELECTIVE NSAIDs</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Nimesulide betadex (or nimesulide)</td><td align="left">689</td><td align="left">52.1</td></tr><tr><td align="left">OTHER DRUGS/TREATMENTS</td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Various, systemic (ASA, paracetamol, corticosteroids, centrally acting myorelaxants)</td><td align="left">46</td><td align="left">3.5</td></tr><tr><td align="left">&#x02003;&#x02003;Various, topical (transcutaneous or intraarticular)</td><td align="left">44</td><td align="left">3.3</td></tr><tr><td align="left">&#x02003;&#x02003;Physical treatment (mobilization, iontophoresis, etc.)</td><td align="left">60</td><td align="left">4.5</td></tr></tbody></table></table-wrap><p>Follow-up visits were performed after 29.0 days on average (&#x000b1; 7.69 SD). Only a small number of patients (17; 1.2%) did not attend follow-up visit.</p><sec><title>HRQoL assessment: SF-36</title><p>For all SF-36 domains, the difference between baseline and follow up scores resulted statistically significant (p &#x0003c; 0.001) (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>SF 36 scores (Mean &#x000b1; SE). Baseline vs Follow-up scores. At the ANCOVAs: p &#x0003c; 0.001 for all domains</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">SF-36 domains</td><td align="left">Baseline</td><td align="left">Follow up</td><td align="left">p</td></tr></thead><tbody><tr><td align="left">Physical Functioning</td><td align="left">47.9 &#x000b1; 0.7</td><td align="left">59.3 &#x000b1; 0.7</td><td align="left">&#x0003c;.001</td></tr><tr><td align="left">Role Physical</td><td align="left">27.8 &#x000b1; 1.0</td><td align="left">48.0 &#x000b1; 1.1</td><td align="left">&#x0003c;.001</td></tr><tr><td align="left">Bodily Pain</td><td align="left">31.7 &#x000b1; 0.4</td><td align="left">50.5 &#x000b1; 0.5</td><td align="left">&#x0003c;.001</td></tr><tr><td align="left">General Health</td><td align="left">45.8 &#x000b1; 0.5</td><td align="left">50.0 &#x000b1; 0.5</td><td align="left">&#x0003c;.001</td></tr><tr><td align="left">Vitality</td><td align="left">46.5 &#x000b1; 0.5</td><td align="left">53.2 &#x000b1; 0.5</td><td align="left">&#x0003c;.001</td></tr><tr><td align="left">Social Functioning</td><td align="left">44.1 &#x000b1; 0.6</td><td align="left">65.4 &#x000b1; 0.6</td><td align="left">&#x0003c;.001</td></tr><tr><td align="left">Role Emotional</td><td align="left">46.9 &#x000b1; 1.2</td><td align="left">65.7 &#x000b1; 1.1</td><td align="left">&#x0003c;.001</td></tr><tr><td align="left">Mental Health</td><td align="left">59.2 &#x000b1; 0.5</td><td align="left">65.4 &#x000b1; 0.5</td><td align="left">&#x0003c;.001</td></tr></tbody></table></table-wrap><p>Baseline Present Pain was associated with almost all the SF-36 domains (Table <xref ref-type="table" rid="T4">4</xref>). The presence of concomitant disease(s) resulted in a statistically significant association with 4 domains: Role Physical, Bodily Pain, General Health, Social Functioning. The type of OA treatment was associated with Physical Functioning and Bodily Pain. OA localization and age was associated with only one domain: Physical Functioning and Role Physical respectively. Gender and body weight did not correlate with any SF-36 domain.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Detected statistical significances on SF-36 delta scores. The p values resulted from the ANCOVAs are indicated.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">SF-36 domains</td><td align="center" colspan="7">Covariates</td></tr><tr><td></td><td align="left">Age</td><td align="left">Gender</td><td align="left">Body weight</td><td align="left">OA localization</td><td align="left">Present Pain</td><td align="left">Concomitant diseases</td><td align="left">Treatment</td></tr></thead><tbody><tr><td align="left">Physical Functioning</td><td></td><td></td><td></td><td align="left">0.021</td><td align="left">0.0001</td><td></td><td align="left">0.020</td></tr><tr><td align="left">Role Physical</td><td align="left">0.022</td><td></td><td></td><td></td><td></td><td align="left">0.007</td><td></td></tr><tr><td align="left">Bodily Pain</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td align="left">0.0001</td><td align="left">0.006</td></tr><tr><td align="left">General Health</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td align="left">0.003</td><td></td></tr><tr><td align="left">Vitality</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td></td><td></td></tr><tr><td align="left">Social Functioning</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td align="left">0.003</td><td></td></tr><tr><td align="left">Role Emotional</td><td></td><td></td><td></td><td></td><td align="left">0.007</td><td></td><td></td></tr><tr><td align="left">Mental Health</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td></td><td></td></tr></tbody></table></table-wrap></sec><sec><title>HRQoL assessment: SAT-P factors</title><p>All the differences between baseline and follow up SAT-P factor scores were statistically significant (p &#x0003c; 0.001) (Table <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>SAT-P factor scores (M &#x000b1; SE). Baseline vs Follow-up scores. At the ANCOVAs: p &#x0003c; 0.001 for all Factors.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">SAT-P Factors</td><td align="left">Baseline</td><td align="left">Follow up</td><td align="left">p</td></tr></thead><tbody><tr><td align="left">Psychological functioning</td><td align="left">59.3 &#x000b1; 0.6</td><td align="left">65.5 &#x000b1; 0.5</td><td align="left">p &#x0003c;.001</td></tr><tr><td align="left">Physical functioning</td><td align="left">41.3 &#x000b1; 0.5</td><td align="left">51.9 &#x000b1; 0.5</td><td align="left">p &#x0003c;.001</td></tr><tr><td align="left">Work</td><td align="left">53.3 &#x000b1; 0.7</td><td align="left">57.8 &#x000b1; 0.7</td><td align="left">p &#x0003c;.001</td></tr><tr><td align="left">Sleep/Eating/Leisure</td><td align="left">55.4 &#x000b1; 0.5</td><td align="left">60.9 &#x000b1; 0.5</td><td align="left">p &#x0003c;.001</td></tr><tr><td align="left">Social functioning</td><td align="left">66.0 &#x000b1; 0.6</td><td align="left">70.8 &#x000b1; 0.5</td><td align="left">p &#x0003c;.001</td></tr></tbody></table></table-wrap><p>Baseline pain was significantly associated with all SAT-P factors (Table <xref ref-type="table" rid="T6">6</xref>). The presence of concomitant disease(s) was in a statistically significant association with 3 out of 5 factors: Psychological functioning, Sleep-Eating-Leisure, Social functioning. OA treatment was associated with the factor Sleep-Eating-Leisure.</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Detected statistical significances on SAT-P factors. The p values resulted from the ANCOVAs are indicated</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">SAT-P Factors</td><td align="center" colspan="7">Covariates</td></tr><tr><td></td><td align="left">Age</td><td align="left">Gender</td><td align="left">Body weight</td><td align="left">OA localization</td><td align="left">Present Pain</td><td align="left">Concomitant diseases</td><td align="left">Treatment</td></tr></thead><tbody><tr><td align="left">Psychological functioning</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td align="left">0.022</td><td></td></tr><tr><td align="left">Physical functioning</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td></td><td></td></tr><tr><td align="left">Work</td><td></td><td></td><td></td><td></td><td align="left">0.007</td><td></td><td></td></tr><tr><td align="left">Sleep/Eating/Leisure</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td align="left">0.007</td><td align="left">0.026</td></tr><tr><td align="left">Social functioning</td><td></td><td></td><td></td><td></td><td align="left">0.0001</td><td align="left">0.018</td><td></td></tr></tbody></table></table-wrap></sec><sec><title>HRQoL assessment: SAT-P items</title><p>Figure <xref ref-type="fig" rid="F1">1</xref> shows the graphic representation of baseline and follow up SAT-P item scores. All the differences were statistically significant (p &#x0003c; 0.001).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>SAT-P items: mean scores at baseline and at follow-up. For all the differences (ANCOVAs) p &#x0003c; 0.001.</p></caption><graphic xlink:href="1477-7525-3-14-1"/></fig></sec><sec><title>Clinical outcome of OA treatment: Efficacy and Tolerability</title><p>At follow-up, mean VAS Pain Relief was 61.1 mm (&#x000b1; 24.3 SD).</p><p>In 65% of cases treatment efficacy was evaluated as good or excellent by patients themselves, in 67% of cases it was evaluated as good or excellent by physicians. In 81% of cases treatment tolerability was evaluated as good or excellent by patients themselves, in 84% of cases it was evaluated as good or excellent by physicians. It was evaluated as poor in 7% and 6% of cases respectively (Table <xref ref-type="table" rid="T7">7</xref>).</p><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>OA treatments' evaluations (efficacy and tolerability)</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">Poor</td><td align="left">Moderate</td><td align="left">Good</td><td align="left">Excellent</td><td align="left">Missing data</td></tr><tr><td></td><td align="left">n (%)</td><td align="left">n (%)</td><td align="left">n (%)</td><td align="left">n (%)</td><td align="left">n (%)</td></tr></thead><tbody><tr><td align="left">Efficacy &#x02013; patients</td><td align="left">163 (12.3)</td><td align="left">288 (21.8)</td><td align="left">634 (47.9)</td><td align="left">227 (17.2)</td><td align="left">11 (0.8)</td></tr><tr><td align="left">Efficacy &#x02013; physicians</td><td align="left">129 (9.8)</td><td align="left">292 (22.1)</td><td align="left">634 (47.9)</td><td align="left">257 (19.4)</td><td align="left">11 (0.8)</td></tr><tr><td align="left">Tolerability &#x02013; patients</td><td align="left">93 (7.1)</td><td align="left">147 (11.1)</td><td align="left">712 (53.8)</td><td align="left">359 (27.1)</td><td align="left">12 (0.9)</td></tr><tr><td align="left">Tolerability &#x02013; physicians</td><td align="left">79 (6.0)</td><td align="left">122 (9.2)</td><td align="left">703 (53.1)</td><td align="left">407 (30.8)</td><td align="left">12 (0.9)</td></tr></tbody></table></table-wrap><p>11.1% of patients reported side effects to medical treatment of OA; most of these reactions involved the gastrointestinal system. Poor tolerability led to treatment withdrawal in 6.2% of patients.</p></sec></sec><sec><title>Discussion</title><p>Our study represents, to our knowledge, the largest observational prospective clinical trial carried out in OA patients' subjective HRQoL. The sample size and the very small number of drop-outs could be considered the strenghts of the study.</p><p>A limit of the study could be considered the adoption of the SAT-P which is a new questionnaire, validated on the Italian population [<xref ref-type="bibr" rid="B30">30</xref>], but not previously used in clinical trials or in OA patients. Nevertheless, its psychometric properties have been previously confirmed, and moreover it is the only Italian questionnaire specifically aimed at assessing subjective satisfaction in daily life, independently of the presence of a disease. Its user friendly structure and its easily comprehensible graphical representation could be considered substantial methodological facilities both in research and in clinical practice.</p><p>Finally, the coherence between the data provided by the two HRQoL instruments could confirm that health status and subjective satisfaction partially overlap, and allows us to study the same phenomenon from two different points of view: the objective and the subjective. This could therefore be considered the added value of the study.</p><p>Considering the whole sample, SF-36 results confirm what previous studies have already enlightened in clinical trials: the SF-36 is, according to Kosinski et al. [<xref ref-type="bibr" rid="B35">35</xref>], a suitable instrument for assessing health status in OA, and medical treatment improves functionality levels in daily life aspects.</p><p>The same conclusions could be drawn for the SAT-P: on the whole sample a general improvement of satisfaction levels can be observed in all the 32 items considered. In other words, pharmacological treatment has a significant positive impact on patients' both objective functioning and subjective well-being [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Thanks to the sinergic utility of the two instruments it has been possible to enlight results otherwise left unperceived and whose positive value on patients' life is unquestionable.</p><p>Further investigations are needed in order to better clarify the relationships between perceived pain and pain relief and patients' HRQoL. Mastery, self-efficacy and coping abilities could be significant mediators between these two constructs [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>].</p></sec><sec><title>Conclusion</title><p>From both an objective and a subjective point of view, OA flare-ups' treatment has proved to have positive effects on HRQoL. The sinergic use of a health status measure (SF-36) and of a tool addressing subjective satisfaction (SAT-P) allows to wider the focus on patients' life.</p><p>This methodological approach could help clinicians and researchers in transferring into practice the ICF model issues [<xref ref-type="bibr" rid="B40">40</xref>], with special attention on Activity and Participation and on Environmental Factors.</p></sec><sec><title>List of abbreviations</title><p>ANCOVA Analysis of Covariance</p><p>HRQoL Health Related Quality of Life</p><p>NSAID Non Steroid Anti Inflammatory Drugs</p><p>OA Osteoarthritis</p><p>SAT -P Satisfaction Profile</p><p>SF-36 Medical Outcome Study Short-Form 36 Health Status Survey</p><p>VAS Visual Analogue Scale</p></sec><sec><title>Competing interests</title><p>The author AS is employee of the company that partially funded the study.</p></sec><sec><title>Authors' contributions</title><p>GM: responsible for the design of the study, contributed to the statistical evaluation, contributed to the writing of the paper.</p><p>AG: responsible for the statistical evaluation, contributed to the writing of the paper.</p><p>AS: contributed to the design of the study and data collection, contributed to the statistical evaluation, contributed to revise the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional File 1</title><p>Appendix A &#x02013; Participating Centers</p></caption><media xlink:href="1477-7525-3-14-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study has been partially funded by Italfarmaco SpA, Milan, Italy. We would gratefully acknowledge the recruitment and data collection of the many physicians and nurses who collaborated to our study (in Appendix A all the participating centers are listed [see additional file]).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Bock</surname><given-names>GH</given-names></name><name><surname>Kaptein</surname><given-names>AA</given-names></name><name><surname>Touw-Otten</surname><given-names>F</given-names></name><name><surname>Mulder</surname><given-names>JD</given-names></name></person-group><article-title>Health-related quality of life in patients with osteoarthritis in a family practice setting</article-title><source>Arthritis Care Res</source><year>1995</year><volume>8</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">7794991</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopman-Rock</surname><given-names>M</given-names></name><name><surname>Kraaimaat</surname><given-names>FW</given-names></name><name><surname>Bijlsma</surname><given-names/></name></person-group><article-title>Quality of life in elderly subjects with pain in the hip or knee</article-title><source>Qual Life Res</source><year>1997</year><volume>6</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">9062444</pub-id><pub-id pub-id-type="doi">10.1023/A:1026421629416</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Birrel</surname><given-names>F</given-names></name><name><surname>Croft</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Hosie</surname><given-names>G</given-names></name><name><surname>Macfarlane</surname><given-names>G</given-names></name><name><surname>Silman</surname><given-names>A</given-names></name></person-group><article-title>Health impact of pain in the hip region with and without radiographic evidence of osteoathritis: a study of new attenders to primary care</article-title><source>Ann Rheum Dis</source><year>2000</year><volume>59</volume><fpage>857</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">11053061</pub-id><pub-id pub-id-type="doi">10.1136/ard.59.11.857</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>E</given-names></name><name><surname>Steele</surname><given-names>K</given-names></name></person-group><article-title>Impact of osteoarthritis and analgesic treatment on quality of life of an elderly population</article-title><source>Ann Pharmacother</source><year>1999</year><volume>33</volume><fpage>1154</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">10573311</pub-id><pub-id pub-id-type="doi">10.1345/aph.18411</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Creamer</surname><given-names>P</given-names></name><name><surname>Lethbridge-Cejku</surname><given-names>M</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group><article-title>Factors associated with functional impairment in symtomatic knee osteoarthritis</article-title><source>Rheumatology</source><year>2000</year><volume>39</volume><fpage>490</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">10852978</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/39.5.490</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Bock</surname><given-names>GH</given-names></name><name><surname>Hermans</surname><given-names>J</given-names></name><name><surname>van Marwijk</surname><given-names>HWJ</given-names></name><name><surname>Kaptein</surname><given-names>AA</given-names></name><name><surname>Mulder</surname><given-names>JD</given-names></name></person-group><article-title>Health-related quality of life assessments in osteoarthritis during NSAID treatment</article-title><source>Pharm World Sci</source><year>1996</year><volume>18</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">8873228</pub-id><pub-id pub-id-type="doi">10.1007/BF00717728</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>La Montagna</surname><given-names>G</given-names></name><name><surname>Tirri</surname><given-names>G</given-names></name><name><surname>Cacace</surname><given-names>E</given-names></name><name><surname>Perprgnano</surname><given-names>G</given-names></name><name><surname>Covelli</surname><given-names>M</given-names></name><name><surname>Pipitone</surname><given-names>V</given-names></name><name><surname>D'Agostino</surname><given-names>P</given-names></name><name><surname>Magar&#x000f2;</surname><given-names>M</given-names></name><name><surname>Ferraccioli</surname><given-names>G</given-names></name><name><surname>Mascia</surname><given-names>MT</given-names></name><name><surname>Manzini</surname><given-names>E</given-names></name><name><surname>Minari</surname><given-names>C</given-names></name><name><surname>Barreca</surname><given-names>C</given-names></name><name><surname>Marcolongo</surname><given-names>R</given-names></name><name><surname>Paresce</surname><given-names>E</given-names></name><name><surname>Colombo</surname><given-names>B</given-names></name></person-group><article-title>Quality of life assessment during six months of NSAID treatment [Gonarthrosis and quality of life (GOAL) Study]</article-title><source>Clin Exp Rheumatol</source><year>1998</year><volume>16</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">9543561</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Kong</surname><given-names>SX</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name></person-group><article-title>Gastrointestinal symptoms and health related quality of life in patients with arthritis</article-title><source>J Rheumatol</source><year>2000</year><volume>27</volume><fpage>1373</fpage><lpage>1378</lpage><pub-id pub-id-type="pmid">10852256</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>D</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Skeith</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name></person-group><article-title>Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoathritis of the knee</article-title><source>J Rheumatol</source><year>1999</year><volume>26</volume><fpage>2659</fpage><lpage>2663</lpage><pub-id pub-id-type="pmid">10606379</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>SZ</given-names></name><name><surname>McMillen</surname><given-names>JI</given-names></name><name><surname>Markenson</surname><given-names>JA</given-names></name><name><surname>Dedhiya</surname><given-names>SD</given-names></name><name><surname>Zhao</surname><given-names>WW</given-names></name><name><surname>Osterhaus</surname><given-names>JT</given-names></name><name><surname>Yu</surname><given-names>SS</given-names></name></person-group><article-title>Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib</article-title><source>Pharmacotherapy</source><year>1999</year><volume>19</volume><fpage>1269</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">10555933</pub-id><pub-id pub-id-type="doi">10.1592/phco.19.16.1269.30879</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>SZ</given-names></name><name><surname>Dedhiya</surname><given-names>SD</given-names></name><name><surname>Bocanegra</surname><given-names>TS</given-names></name><name><surname>Fort</surname><given-names>JG</given-names></name><name><surname>Kuss</surname><given-names>ME</given-names></name><name><surname>Rush</surname><given-names>SM</given-names></name></person-group><article-title>Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee</article-title><source>Clin Ther</source><year>1999</year><volume>21</volume><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">10090436</pub-id><pub-id pub-id-type="doi">10.1016/S0149-2918(00)88279-X</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yocum</surname><given-names>D</given-names></name><name><surname>Fleischmann</surname><given-names>R</given-names></name><name><surname>Dalgin</surname><given-names>P</given-names></name><name><surname>Caldwell</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>D</given-names></name><name><surname>Roszko</surname><given-names>P</given-names></name></person-group><article-title>Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial</article-title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><fpage>2947</fpage><lpage>2954</lpage><pub-id pub-id-type="pmid">11041902</pub-id><pub-id pub-id-type="doi">10.1001/archinte.160.19.2947</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KW</given-names></name><name><surname>Avis</surname><given-names>NE</given-names></name><name><surname>Assmann</surname><given-names>SF</given-names></name></person-group><article-title>Distinguishing between quality of life and health status in quality of life research: a meta-analysis</article-title><source>Qual Life Res</source><year>1999</year><volume>8</volume><fpage>447</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">10474286</pub-id><pub-id pub-id-type="doi">10.1023/A:1008928518577</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>TM</given-names></name><name><surname>Feinstein</surname><given-names>AR</given-names></name></person-group><article-title>A critical appraisal of the quality of quality-of-life measurements</article-title><source>JAMA</source><year>1994</year><volume>272</volume><fpage>619</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">7726894</pub-id><pub-id pub-id-type="doi">10.1001/jama.272.8.619</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>RM</given-names></name><collab>Editorial</collab></person-group><article-title>The patient-physician relationship: JAMA focuses of the center of medicine</article-title><source>JAMA</source><year>1996</year><volume>275</volume><fpage>147</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">8531312</pub-id><pub-id pub-id-type="doi">10.1001/jama.275.2.147</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muldoon</surname><given-names>MF</given-names></name><name><surname>Barger</surname><given-names>SD</given-names></name><name><surname>Flory</surname><given-names>JD</given-names></name><name><surname>Manuck</surname><given-names>SB</given-names></name></person-group><article-title>What are quality of life measurements measuring?</article-title><source>BMJ</source><year>1998</year><volume>316</volume><fpage>542</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">9501721</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rapkin</surname><given-names>BD</given-names></name><name><surname>Shwartz</surname><given-names>CE</given-names></name></person-group><article-title>Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift</article-title><source>Health and Quality of Life Outcomes</source><year>2004</year><volume>2</volume><fpage>14</fpage><pub-id pub-id-type="pmid">15023229</pub-id><pub-id pub-id-type="doi">10.1186/1477-7525-2-14</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shwartz</surname><given-names>CE</given-names></name><name><surname>Rapkin</surname><given-names>BD</given-names></name></person-group><article-title>Reconsidering the psychometrics of quality of life assessment in light of response shift and appraisal</article-title><source>Health and Quality of Life Outcomes</source><year>2004</year><volume>2</volume><fpage>16</fpage><pub-id pub-id-type="pmid">15038830</pub-id><pub-id pub-id-type="doi">10.1186/1477-7525-2-16</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asadi-Lari</surname><given-names>M</given-names></name><name><surname>Tamburini</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>D</given-names></name></person-group><article-title>Patients' needs, satisfaction, and health related quality of life: Towards a comprehensive model</article-title><source>Health and Quality of Life Outcomes</source><year>2004</year><volume>2</volume><fpage>32</fpage><pub-id pub-id-type="pmid">15225377</pub-id><pub-id pub-id-type="doi">10.1186/1477-7525-2-32</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>DF</given-names></name><name><surname>Tulsky</surname><given-names>DS</given-names></name></person-group><article-title>Measuring quality of life today: methodological aspects</article-title><source>Oncology</source><year>1990</year><volume>5</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">2143408</pub-id></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Berzon</surname><given-names>RA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Staquet MJ, Hays RD, Fayers PM</surname></name></person-group><article-title>Understanding and using health-related quality of life instrument within clinical research studies</article-title><source>Quality of Life Assessment in Clinical Trials</source><year>1998</year><publisher-name>New York: Oxford University Press</publisher-name><fpage>3</fpage><lpage>15</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>AJ</given-names></name><name><surname>Gibson</surname><given-names>B</given-names></name><name><surname>Robinson</surname><given-names>PG</given-names></name></person-group><article-title>Measuring quality of life. Is quality of life determined by expectations or experience?</article-title><source>BMJ</source><year>2001</year><volume>322</volume><fpage>1240</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11358783</pub-id><pub-id pub-id-type="doi">10.1136/bmj.322.7296.1240</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higginsin</surname><given-names>IJ</given-names></name><name><surname>Carr</surname><given-names>AJ</given-names></name></person-group><article-title>Measuring quality of life. Using quality of life measures in the clinical setting</article-title><source>BMJ</source><year>2001</year><volume>322</volume><fpage>1297</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">11375237</pub-id><pub-id pub-id-type="doi">10.1136/bmj.322.7297.1297</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>AJ</given-names></name><name><surname>Higginson</surname><given-names>IJ</given-names></name></person-group><article-title>Measuring quality of life. Are quality of life measures patient centred?</article-title><source>BMJ</source><year>2001</year><volume>322</volume><fpage>1357</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">11387189</pub-id><pub-id pub-id-type="doi">10.1136/bmj.322.7298.1357</pub-id></citation></ref><ref id="B25"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>RD</given-names></name></person-group><article-title>The Classification of Osteoarthritis. Journal Rheumatology</article-title><year>2001</year><volume>22</volume><fpage>42</fpage><lpage>43</lpage></citation></ref><ref id="B26"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Huskisson</surname><given-names>EC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Melzack R</surname></name></person-group><article-title>Visual Analogue Scales</article-title><source>Pain measurement and assessment</source><year>1983</year><publisher-name>New York: Raven Press</publisher-name><fpage>33</fpage><lpage>37</lpage></citation></ref><ref id="B27"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Gandek</surname><given-names>B</given-names></name></person-group><source>SF-36 Health Survey: Manual and interpretation guide</source><year>1993</year><publisher-name>Boston, Mass: The Health Institute, New England Medical Center</publisher-name></citation></ref><ref id="B28"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Apolone</surname><given-names>G</given-names></name><name><surname>Mosconi</surname><given-names>P</given-names></name><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><source>Questionario sullo stato di salute SF-36: manuale d'uso e guida all'interpretazione dei risultati</source><year>1997</year><publisher-name>Milano: Guerini e Associati</publisher-name></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Apolone</surname><given-names>G</given-names></name><name><surname>Mosconi</surname><given-names>P</given-names></name></person-group><article-title>The Italian SF-36 Health Survey: traslation, validation and norming</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>1025</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">9817120</pub-id><pub-id pub-id-type="doi">10.1016/S0895-4356(98)00094-8</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Majani</surname><given-names>G</given-names></name><name><surname>Pierobon</surname><given-names>A</given-names></name><name><surname>Giardini</surname><given-names>A</given-names></name><name><surname>Callegari</surname><given-names>S</given-names></name></person-group><article-title>Satisfaction Profile (SAT-P) in 732 patients: focus on subjectivity in HRQoL assessment</article-title><source>Psychol Health</source><year>2000</year><volume>15</volume><fpage>409</fpage><lpage>422</lpage></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>MP</given-names></name><name><surname>Karoly</surname><given-names>P</given-names></name><name><surname>O'Riordan</surname><given-names>EF</given-names></name><name><surname>Bland</surname><given-names>F</given-names><suffix>Jr</suffix></name><name><surname>Burns</surname><given-names>RS</given-names></name></person-group><article-title>The subjective experience of acute pain: An assessment of the utility of 10 indices</article-title><source>Clin J Pain</source><year>1989</year><volume>5</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">2520397</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname><given-names>J</given-names></name><name><surname>Ashton</surname><given-names>R</given-names></name><name><surname>Chant</surname><given-names>D</given-names></name></person-group><article-title>Pain intensity measurement on chronic low back pain</article-title><source>Clin J Pain</source><year>1991</year><volume>7</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">1839716</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>AL</given-names></name><name><surname>Greenfield</surname><given-names>S</given-names></name><name><surname>Hays</surname><given-names>RD</given-names></name><name><surname>Wells</surname><given-names>K</given-names></name><name><surname>Rogers</surname><given-names>WH</given-names></name><name><surname>Berry</surname><given-names>SD</given-names></name><name><surname>McGlynn</surname><given-names>EA</given-names></name><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><article-title>Functional status and well-being of patients with chronic conditions</article-title><source>JAMA</source><year>1989</year><volume>262</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">2754790</pub-id><pub-id pub-id-type="doi">10.1001/jama.262.7.907</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brazier</surname><given-names>JE</given-names></name><name><surname>Harper</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>NMB</given-names></name><name><surname>O'Cathain</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>KJ</given-names></name><name><surname>Usherwood</surname><given-names>T</given-names></name><name><surname>Westlake</surname><given-names>L</given-names></name></person-group><article-title>Validating the SF-36 Health Survey Questionnaire: new outcome measure for primary care</article-title><source>BMJ</source><year>1992</year><volume>305</volume><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">1285753</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>SD</given-names></name><name><surname>Hatoum</surname><given-names>HT</given-names></name><name><surname>Kong</surname><given-names>SX</given-names></name><name><surname>Ware</surname><given-names>JE</given-names></name></person-group><article-title>The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoathritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability</article-title><source>Med Care</source><year>1999</year><volume>37</volume><fpage>MS10</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">10335740</pub-id><pub-id pub-id-type="doi">10.1097/00005650-199905001-00002</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Majani</surname><given-names>G</given-names></name><name><surname>Pierobon</surname><given-names>A</given-names></name><name><surname>Giardini</surname><given-names>A</given-names></name><name><surname>Callegari</surname><given-names>S</given-names></name><name><surname>Opasich</surname><given-names>C</given-names></name><name><surname>Cobelli</surname><given-names>F</given-names></name><name><surname>Tavazzi</surname><given-names>L</given-names></name></person-group><article-title>Relationship between psychological profile and cardiological variables in chronic heart failure: the role of patient subjectivity</article-title><source>Eur Heart J</source><year>1999</year><volume>20</volume><fpage>1579</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">10529326</pub-id><pub-id pub-id-type="doi">10.1053/euhj.1999.1712</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Majani</surname><given-names>G</given-names></name><name><surname>Baiardini</surname><given-names>I</given-names></name><name><surname>Giardini</surname><given-names>A</given-names></name><name><surname>Senna</surname><given-names>GE</given-names></name><name><surname>Minale</surname><given-names>P</given-names></name><name><surname>D'Ulisse</surname><given-names>S</given-names></name><name><surname>Ciprandi</surname><given-names>G</given-names></name><name><surname>Canonica</surname><given-names>GW</given-names></name></person-group><article-title>Health-related quality of life assessment in young adults with seasonal allergic rhinitis</article-title><source>Allergy</source><year>2001</year><volume>56</volume><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">11284798</pub-id><pub-id pub-id-type="doi">10.1034/j.1398-9995.2001.00852.x</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCracken</surname><given-names>LM</given-names></name></person-group><article-title>Learning to live with the pain: acceptance of pain predicts adjustment in persons with chronic pain</article-title><source>Pain</source><year>1998</year><volume>74</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">9514556</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3959(97)00146-2</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnstein</surname><given-names>P</given-names></name><name><surname>Caudill</surname><given-names>M</given-names></name><name><surname>Mandle</surname><given-names>CL</given-names></name><name><surname>Norris</surname><given-names>A</given-names></name><name><surname>Beasley</surname><given-names>R</given-names></name></person-group><article-title>Self-efficacy as a mediator of the relationship between pain intensity, disability and depression in chronic pain patients</article-title><source>Pain</source><year>1999</year><volume>80</volume><fpage>483</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">10342410</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3959(98)00220-6</pub-id></citation></ref><ref id="B40"><citation citation-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>International Classification of Functioning, Disability and Health</source><year>2001</year><publisher-name>World Health Organization: Geneva</publisher-name></citation></ref></ref-list></back></article>



